MIT Technology Review · Jul 31, 2026
MIT Technology Review reports on Montana’s experimental drug rules
Markdown · JSON · Original source
MIT Technology Review’s July 31, 2026, edition of The Download reports on Montana’s plan to make experimental drugs available through clinics. The newsletter says biotech companies with drugs that have undergone preliminary testing can apply to a new review board for approval, then sell approved treatments through experimental treatment clinics. It describes the law as unusual because access may be available to anyone who gives informed consent and can pay. For some people in the longevity community, that prospect is hopeful; others consider it unethical and dangerous. The newsletter also follows Kris DeVault’s effort to access a drug that might help his son Brody, who has creatine transporter deficiency. The drug remains in early development, has been tested in animals and a small number of healthy adults, and doctors cannot prescribe it. DeVault knows it might not work, but is trying to obtain it anyway. Together, these accounts show the tension the newsletter highlights: expanded access may matter to people facing conditions without cures, while the treatment’s potential benefit and risks remain uncertain. The newsletter does not explain how the review board will assess applications or what safeguards clinics will use.
Headline and summary by Escape Meridian, prepared by Luna from the attributed source. A source check is not independent confirmation of the source’s claims.
Original source
MIT Technology Review · Article
Source details
Original source date: Jul 31, 2026 (2026-07-31T12:16:00Z).
Date basis: Date from the publisher’s own records, through its API.
Added to Escape Meridian: 2026-11-09T03:28:33.196Z. First observed: 2026-11-08T23:37:41.127Z. Retrieved: 2026-11-08T23:39:36.716Z.
Referenced by
Recorded citations and public file attachments. A reference alone does not establish agreement or influence.
No public references recorded here yet.
Limits
Text as retrieved on November 8, 2026; originally published July 31, 2026. This newsletter preview does not provide the review board’s application criteria or describe the safeguards clinics will use. The newsletter says the drug might help, but provides no evidence in this text that it works or details of its risks.
Open question
What evidence and safeguards will Montana’s review board require before a company can sell an experimental treatment through a clinic?
Source-stated
MIT Technology Review’s newsletter says Montana’s law allows biotech companies with drugs that have undergone preliminary testing to apply to a review board, and approved treatments can be sold through experimental treatment clinics.
biotech companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval.
Source-stated
The newsletter says access may be available to anyone who gives informed consent and can pay, and reports differing views of that prospect.
Access to drugs is theoretically available to anyone who gives informed consent and can pay. For some, especially people in the longevity community, that’s a hopeful and exciting prospect. But to others, it’s unethical and dangerous.
Source-stated
The newsletter reports that Brody DeVault has creatine transporter deficiency and that a drug his father hopes to access remains at an early stage of development.
That drug is still in the early stages of development and has only been tested in animals and a small number of healthy adults. Doctors can’t prescribe it.
Escape Meridian interpretation
Escape Meridian reads the two accounts as illustrating a tension between possible access for people facing conditions without cures and uncertainty about whether an experimental treatment will help.
There are no cures for Brody’s condition. But DeVault has learned of a company developing a drug that might help.
Source and contributor context
MIT Technology Review · Publisher
The publisher is identified here. No individual author has been inferred.
Source media
Media retrieval status: unchecked.
Terms and references
Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.
Editorial provenance
Version 1. Publication ID: d76fb235-2885-de3b-ab3e-17a2a23c3eba.
Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.
Source check: passed by anthropic/claude-opus-5.5 on 2026-11-09T03:24:15.280Z. This checks fidelity to the source, not whether its claims are independently true.
Editorial selection: accept; reasons: bridge_admitted_by_model.
Observation: 5aad422dda6455179c378060746ab7254626cb0a0e8294d5345ccebf4bc4a8c7. Source text hash: 07d545757daa577c8269f4f072b896e67a5d454d7052218702c607ce4014a581.
Revision and source-check history
Version 1 · 2026-11-09T03:28:33.196Z
MIT Technology Review reports on Montana’s experimental drug rules
MIT Technology Review’s July 31, 2026, edition of The Download reports on Montana’s plan to make experimental drugs available through clinics. The newsletter says biotech companies with drugs that have undergone preliminary testing can apply to a new review board for approval, then sell approved treatments through experimental treatment clinics. It describes the law as unusual because access may be available to anyone who gives informed consent and can pay. For some people in the longevity community, that prospect is hopeful; others consider it unethical and dangerous. The newsletter also follows Kris DeVault’s effort to access a drug that might help his son Brody, who has creatine transporter deficiency. The drug remains in early development, has been tested in animals and a small number of healthy adults, and doctors cannot prescribe it. DeVault knows it might not work, but is trying to obtain it anyway. Together, these accounts show the tension the newsletter highlights: expanded access may matter to people facing conditions without cures, while the treatment’s potential benefit and risks remain uncertain. The newsletter does not explain how the review board will assess applications or what safeguards clinics will use.
Original source
MIT Technology Review · Article
Source details
Original source date: Jul 31, 2026 (2026-07-31T12:16:00Z).
Date basis: Date from the publisher’s own records, through its API.
Added to Escape Meridian: 2026-11-09T03:28:33.196Z. First observed: 2026-11-08T23:37:41.127Z. Retrieved: 2026-11-08T23:39:36.716Z.
Limits
Text as retrieved on November 8, 2026; originally published July 31, 2026. This newsletter preview does not provide the review board’s application criteria or describe the safeguards clinics will use. The newsletter says the drug might help, but provides no evidence in this text that it works or details of its risks.
Open question
What evidence and safeguards will Montana’s review board require before a company can sell an experimental treatment through a clinic?
Source-stated
MIT Technology Review’s newsletter says Montana’s law allows biotech companies with drugs that have undergone preliminary testing to apply to a review board, and approved treatments can be sold through experimental treatment clinics.
biotech companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval.
Source-stated
The newsletter says access may be available to anyone who gives informed consent and can pay, and reports differing views of that prospect.
Access to drugs is theoretically available to anyone who gives informed consent and can pay. For some, especially people in the longevity community, that’s a hopeful and exciting prospect. But to others, it’s unethical and dangerous.
Source-stated
The newsletter reports that Brody DeVault has creatine transporter deficiency and that a drug his father hopes to access remains at an early stage of development.
That drug is still in the early stages of development and has only been tested in animals and a small number of healthy adults. Doctors can’t prescribe it.
Escape Meridian interpretation
Escape Meridian reads the two accounts as illustrating a tension between possible access for people facing conditions without cures and uncertainty about whether an experimental treatment will help.
There are no cures for Brody’s condition. But DeVault has learned of a company developing a drug that might help.
Source and contributor context
MIT Technology Review · Publisher
The publisher is identified here. No individual author has been inferred.
Source media
Media retrieval status: unchecked.
Terms and references
Reference context selected by Escape Meridian; separate from source evidence. Entity mentions do not establish authorship, involvement or endorsement.
Editorial provenance
Version 1. Publication ID: d76fb235-2885-de3b-ab3e-17a2a23c3eba.
Prepared by openai/gpt-6-luna; grounding review by anthropic/claude-opus-5.5.
Source check: passed by anthropic/claude-opus-5.5 on 2026-11-09T03:24:15.280Z. This checks fidelity to the source, not whether its claims are independently true.
Editorial selection: accept; reasons: bridge_admitted_by_model.
Observation: 5aad422dda6455179c378060746ab7254626cb0a0e8294d5345ccebf4bc4a8c7. Source text hash: 07d545757daa577c8269f4f072b896e67a5d454d7052218702c607ce4014a581.
passed · 2026-11-09T03:24:15.280Z · anthropic/claude-opus-5.5
Publication: d76fb235-2885-de3b-ab3e-17a2a23c3eba
attribution — pass: The reading attributes the content to MIT Technology Review's The Download newsletter. That is one newsletter issue whose items carry the publication's own commentary, so it is not a bare listing. The Montana and DeVault items are bylined Jessica Hamzelou. Attributing them to the newsletter does not misassign any claim.
This is today's edition of The Download, our weekday newsletter
summary — pass: The title, summary and question accurately reflect the Montana right-to-try item and the DeVault story, including the split views and the drug's early stage. Central terms such as creatine transporter deficiency and informed consent are understandable from context or the source's own gloss. Omitting the $12,500 fee and the as-few-as-10-people testing detail is a minor gap that does not distort meaning. The question follows from details the source omits.
Montana’s latest right-to-try legislation is unique.
date — pass: July 31, 2026 matches the UTC calendar day of originalPublished, 2026-07-31T12:16Z. modifiedAt precedes publication, so no post-publication edit is indicated. The reading uses no later sidebar items, such as the Deep Dive links, and does not present the clinics, expected around year's end, as having opened. The evidence kind is publisher-page, so no archive disclosure is required.
the first of which is likely to be up and running around the end of this year
support — pass: Each claim matches its quoted excerpt. The tension framing is labeled as Escape Meridian interpretation and phrased conditionally. The limitations correctly note that the newsletter gives no review-board criteria, clinic safeguards or efficacy evidence. The reading invents no benefits or costs.
DeVault knows the drug might not work. But he’s doing all he can to access it regardless.
media — pass: No media was selected and no verified media candidates were supplied, so there is no identity or relevance issue.
Challenge or correct this reading
Send a correction or an opposing source with this reading’s URL. Disagreement and uncertainty can remain unresolved.